Patents by Inventor Jason Goodrich
Jason Goodrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250145665Abstract: Disclosed are macrocyclic peptide compounds or a salt thereof, which are useful as modulators of TNF?, and pharmaceutical compositions comprising such compounds. These compounds may be useful in treating cancers, inflammatory and autoimmune diseases.Type: ApplicationFiled: July 31, 2024Publication date: May 8, 2025Inventors: Yong Zhang, Alaric J. Dyckman, Ving G. Lee, Zheming Ruan, Jason Goodrich, Lidet A. Negash, Saleem Ahmad, Hong Wu, John Hynes, Michael A. Poss, Alexander C. Brueckner, Sirish Kaushik Lakkaraju
-
Patent number: 11952434Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.Type: GrantFiled: April 20, 2022Date of Patent: April 9, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell
-
Publication number: 20230101323Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.Type: ApplicationFiled: April 20, 2022Publication date: March 30, 2023Applicant: Bristol-Myers Squibb CompanyInventors: Kevin W. GILLMAN, Jason GOODRICH, Kenneth M. BOY, Yunhui ZHANG, Claudio MAPELLI, Michael A. POSS, Paul Michael SCOLA, David R. LANGLEY, Nicholas A. MEANWELL
-
Patent number: 11358988Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.Type: GrantFiled: December 11, 2019Date of Patent: June 14, 2022Assignee: Bristol-Myers Squibb CompanyInventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell
-
Patent number: 11066445Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.Type: GrantFiled: June 21, 2018Date of Patent: July 20, 2021Assignee: Bristol-Myers Squibb CompanyInventors: Kevin W. Gillman, Jason Goodrich, Li-Qiang Sun, Eric Mull, David R. Langley, Paul Michael Scola
-
Patent number: 10988507Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.Type: GrantFiled: November 6, 2017Date of Patent: April 27, 2021Assignee: bristol-myers squibb companyInventors: Kevin W. Gillman, Jason Goodrich, David R. Langley, Paul Michael Scola
-
Publication number: 20200216498Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.Type: ApplicationFiled: December 11, 2019Publication date: July 9, 2020Applicant: Bristol-Myers Squibb CompanyInventors: Kevin W. GILLMAN, Jason GOODRICH, Kenneth M. BOY, Yunhui ZHANG, Claudio MAPELLI, Michael A. POSS, Paul Michael SCOLA, David R. LANGLEY, Nicholas A. MEANWELL
-
Publication number: 20200172578Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 pro-tein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.Type: ApplicationFiled: June 21, 2018Publication date: June 4, 2020Applicant: Bristol-Myers Squibb CompanyInventors: Kevin W. GILLMAN, Jason GOODRICH, Li-Qiang SUN, Eric MULL, David R. LANGLEY, Paul Michael SCOLA
-
Patent number: 10633419Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.Type: GrantFiled: November 27, 2017Date of Patent: April 28, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell
-
Publication number: 20190322704Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.Type: ApplicationFiled: November 6, 2017Publication date: October 24, 2019Inventors: Kevin W. GILLMAN, Jason GOODRICH, David R. LANGLEY, Paul Michael SCOLA
-
Publication number: 20180086793Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.Type: ApplicationFiled: November 27, 2017Publication date: March 29, 2018Inventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell
-
Patent number: 9856292Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.Type: GrantFiled: November 11, 2015Date of Patent: January 2, 2018Assignee: Bristol-Myers Squibb CompanyInventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell
-
Patent number: 9758487Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: GrantFiled: June 28, 2016Date of Patent: September 12, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Gan Wang, Lawrence G. Hamann
-
Publication number: 20160311778Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: ApplicationFiled: June 28, 2016Publication date: October 27, 2016Inventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Gan Wang, Lawrence G. Hamann
-
Publication number: 20160137696Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.Type: ApplicationFiled: November 11, 2015Publication date: May 19, 2016Inventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Li-Qiang Sun, Qian Zhao, Eric Mull, Eric P. Gillis, Paul Michael Scola
-
Patent number: 9227961Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: GrantFiled: September 17, 2014Date of Patent: January 5, 2016Assignee: Bristol-Myers Squibb CompanyInventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Lawrence G. Hamann
-
Patent number: 9018390Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: GrantFiled: June 17, 2013Date of Patent: April 28, 2015Assignee: Bristol-Myers Squibb CompanyInventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Lawrence G. Hamann
-
Publication number: 20150011754Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: ApplicationFiled: September 17, 2014Publication date: January 8, 2015Inventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Lawrence G. Hamann
-
Patent number: 8846023Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: GrantFiled: September 9, 2013Date of Patent: September 30, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Gan Wang, Lawrence G. Hamann
-
Patent number: 8788897Abstract: A path-based crosstalk fault model is used in conjunction with a built-in self-test (BIST) and software capability for automatic test pattern generation. The solution allows for test patterns to be generated that maximize switching activity as well as inductive and capacitive crosstalk. The path based fault model targets the accumulative effect of crosstalk along a particular net (“victim” path), as compared with the discrete nets used in conventional fault models. The BIST solution allows for full controllability of the target paths and any associated aggressors. The BIST combined with automatic test pattern generation software enables defect detection and silicon validation of delay defects on long parallel nets.Type: GrantFiled: September 28, 2012Date of Patent: July 22, 2014Assignee: Texas Instruments IncorporatedInventors: Nisar Ahmed, Corey Jason Goodrich, Xiao Liu, Chris Therrien